ADMA Biologics, Inc. (ADMA)
After hours:
| Previous Close | 3.1600 |
| Open | 3.1400 |
| Bid | 3.2500 x 3000 |
| Ask | 3.3100 x 21500 |
| Day's Range | 3.1100 - 3.3300 |
| 52 Week Range | 1.1700 - 3.4700 |
| Volume | |
| Avg. Volume | 3,040,533 |
| Market Cap | 639.525M |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4900 |
| Earnings Date | Nov 09, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- Simply Wall St.
ADMA Biologics Third Quarter 2022 Earnings: Beats Expectations
ADMA Biologics ( NASDAQ:ADMA ) Third Quarter 2022 Results Key Financial Results Revenue: US$41.1m (up 99% from 3Q...
- Zacks
Adma Biologics (ADMA) Reports Q3 Loss, Tops Revenue Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of 0% and 18.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update
3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase Raising FY 2022 Total Revenue Guidance to $145 Million From $130 Million Previously Gross Profit Growth and Narrowing Net Losses Expected into 2023 Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharm
